Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Exeantide in Type 2 Diabetes on Insulin

NCT01154933
Conditions
Type 2 Diabetes
Interventions
exenatide 5 mcg, exenatide 10 mcg, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Exenatide, Normal Saline
Drug · Other
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Completed Phase 1Phase 2 Interventional Results available

Exenatide Once Weekly for Smoking Cessation

NCT02975297
Conditions
Smoking Cessation
Interventions
Exenatide, NRT, Counseling, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cocaine Use Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson Disease
Interventions
NLY01, Vehicle
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 49 more
Completed Phase 1Phase 2 Interventional Results available

Intravenous Exenatide (Byetta) During Surgery

NCT00882050
Conditions
Euglycemia, Hypoglycemia, Hyperglycemia
Interventions
Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

NCT03672604
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
NLY01
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739
Conditions
Prediabetes, Obesity
Interventions
Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas